Denosumab-related osteonecrosis of the external auditory
canal-benefit of the early surgical management

J 2024

Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management

PEŘINA, Vojtěch, Richard SALZMAN and Jana TREGLEROVÁ

Basic information

Original name

Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management

Authors

PEŘINA, Vojtěch (203 Czech Republic, belonging to the institution), Richard SALZMAN (703 Slovakia) and Jana TREGLEROVÁ (203 Czech Republic, belonging to the institution)

Edition

ENT-EAR NOSE & THROAT JOURNAL, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2024, 0145-5613

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30206 Otorhinolaryngology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.300 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1177/01455613211053389

UT WoS

000710707200001

Keywords in English

osteonecrosis; surgical treatment; denosomab; auditory canal; ear

Abstract

V originále

Background: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM). Both the bisphosphonates (BP) and denosumab typically used in this indication were shown to be effective and relatively safe. Obviously, this medication could have some adverse effects; one of them is osteonecrosis of the external auditory canal. Only sporadic cases of external auditory canal osteonecrosis have been published yet. Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, including denosumab administration. She was diagnosed with osteonecroses in the jaw and ear canal. The necrotic bones in both regions were resected with primary wound closure. Both affected sites healed well with no signs of necrosis recurrence. Conclusions: Osteonecrosis of the external auditory canal is a rare but probably underdiagnosed complication of antiresorptive medication. It has a negative impact on patient quality of life if left untreated. Early surgical treatment appears to be effective. The authors highlight several similarities with medication-related osteonecrosis of the jaw. Therefore, an analogous disease staging and treatment rationale is suggested.

Citovat

PEŘINA, Vojtěch, Richard SALZMAN and Jana TREGLEROVÁ. Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management. ENT-EAR NOSE & THROAT JOURNAL. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2024, vol. 103, No 5, p. 277-281. ISSN 0145-5613. Available from: https://dx.doi.org/10.1177/01455613211053389.

@article{1803319,
   author = {Peřina, Vojtěch and Salzman, Richard and Treglerová, Jana},
   article_location = {THOUSAND OAKS},
   article_number = {5},
   doi = {http://dx.doi.org/10.1177/01455613211053389},
   keywords = {osteonecrosis; surgical treatment; denosomab; auditory canal; ear},
   language = {eng},
   issn = {0145-5613},
   journal = {ENT-EAR NOSE & THROAT JOURNAL},
   title = {Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management},
   url = {https://doi.org/10.1177/01455613211053389},
   volume = {103},
   year = {2024}
}

TY  - JOUR
ID  - 1803319
AU  - Peřina, Vojtěch - Salzman, Richard - Treglerová, Jana
PY  - 2024
TI  - Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management
JF  - ENT-EAR NOSE & THROAT JOURNAL
VL  - 103
IS  - 5
SP  - 277-281
EP  - 277-281
PB  - SAGE PUBLICATIONS INC
SN  - 01455613
KW  - osteonecrosis
KW  - surgical treatment
KW  - denosomab
KW  - auditory canal
KW  - ear
UR  - https://doi.org/10.1177/01455613211053389
N2  - Background: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM). Both the bisphosphonates (BP) and denosumab typically used in this indication were shown to be effective and relatively safe. Obviously, this medication could have some adverse effects; one of them is osteonecrosis of the external auditory canal. Only sporadic cases of external auditory canal osteonecrosis have been published yet. Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, including denosumab administration. She was diagnosed with osteonecroses in the jaw and ear canal. The necrotic bones in both regions were resected with primary wound closure. Both affected sites healed well with no signs of necrosis recurrence. Conclusions: Osteonecrosis of the external auditory canal is a rare but probably underdiagnosed complication of antiresorptive medication. It has a negative impact on patient quality of life if left untreated. Early surgical treatment appears to be effective. The authors highlight several similarities with medication-related osteonecrosis of the jaw. Therefore, an analogous disease staging and treatment rationale is suggested.
ER  -

PEŘINA, Vojtěch, Richard SALZMAN and Jana TREGLEROVÁ. Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management. \textit{ENT-EAR NOSE \&{} THROAT JOURNAL}. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2024, vol.~103, No~5, p.~277-281. ISSN~0145-5613. Available from: https://dx.doi.org/10.1177/01455613211053389.

Detailed Information on Publication Record